Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor

• Published in: PloS one Vol. 10; no. 11; p. e0142845
• Main Authors: Spector, Neil L, Robertson, Faith C, Bacus, Sarah, Blackwell, Kimberly, Smith, Deborah A, Glenn, Kelli, Cartee, Leanne, Harris, Jennifer, Kimbrough, Carie L, Gittelman, Mark, Avisar, Eli, Beitsch, Peter, Koch, Kevin M
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 16.11.2015; Public Library of Science (PLoS)
• Subjects: Administration, Oral; Adult; Animals; Antineoplastic agents; Antineoplastic Agents - blood; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - therapeutic use; Area Under Curve; Biological effects; Blood; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Cancer; Cell Line, Tumor; Chromatography, High Pressure Liquid; Clinical trials; Cytotoxicity; Dosage; Dosing; Drosophila; Drug Administration Schedule; Drug Dosage Calculations; Drug dosages; Epidermal growth factor; Epidermal growth factor receptors; ErbB-2 protein; Experimental design; Female; Gastrointestinal system; Genetic aspects; Growth factor receptors; Half-Life; Humans; Immunohistochemistry; Inhibitor drugs; Insects; Kidneys; Kinases; Laboratory animals; Life assessment; Liver; Medical research; Medicine; Mice; Mice, SCID; Optimization; Patients; Phosphorylation; Phosphorylation - drug effects; Plasma; Protein-tyrosine kinase; Quinazolines - blood; Quinazolines - pharmacokinetics; Quinazolines - therapeutic use; Receptor, Epidermal Growth Factor - antagonists & inhibitors; Receptor, Epidermal Growth Factor - metabolism; Receptors; ROC Curve; Studies; Tandem Mass Spectrometry; Transplantation, Heterologous; Tumors; Tyrosine; Xenografts; Xenotransplantation; United States; North Carolina; United States > US
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0142845

The paradigm shift in cancer treatment from cytotoxic drugs to tumor targeted therapies poses new challenges, including optimization of dose and schedule based on a biologically effective dose, rather than the historical maximum tolerated dose. Optimal dosing is currently determined using concentrations of tyrosine kinase inhibitors in plasma as a surrogate for tumor concentrations. To examine this plasma-tumor relationship, we explored the association between lapatinib levels in tumor and plasma in mice and humans, and those effects on phosphorylation of human epidermal growth factor receptors (HER) in human tumors. Mice bearing BT474 HER2+ human breast cancer xenografts were dosed once or twice daily (BID) with lapatinib. Drug concentrations were measured in blood, tumor, liver, and kidney. In a randomized phase I clinical trial, 28 treatment-naïve female patients with early stage HER2+ breast cancer received lapatinib 1000 or 1500 mg once daily (QD) or 500 mg BID before evaluating steady-state lapatinib levels in plasma and tumor. In mice, lapatinib levels were 4-fold higher in tumor than blood with a 4-fold longer half-life. Tumor concentrations exceeded the in vitro IC90 (~ 900 nM or 500 ng/mL) for inhibition of HER2 phosphorylation throughout the 12-hour dosing interval. In patients, tumor levels were 6- and 10-fold higher with QD and BID dosing, respectively, compared to plasma trough levels. The relationship between tumor and plasma concentration was complex, indicating multiple determinants. HER receptor phosphorylation varied depending upon lapatinib tumor concentrations, suggestive of changes in the repertoire of HER homo- and heterodimers. Plasma lapatinib concentrations underestimated tumor drug levels, suggesting that optimal dosing should be focused on the site of action to avoid to inappropriate dose escalation. Larger clinical trials are required to determine optimal dose and schedule to achieve tumor concentrations that maximally inhibit HER receptors. NCT00359190.